



The Alliance for Regenerative Medicine Announces Election of 2026 Board of Directors

Phoenix, AZ – October 6, 2025

The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization championing the benefits of engineered cell therapies and genetic medicines, today announced the election of its 2026 Board of Directors.

"I'm pleased to welcome these talented and passionate cell and gene therapy leaders to the ARM Board of Directors at a pivotal time for the field," said Bob Smith, ARM Board Chair. "Their collective expertise and leadership will help us advance innovative science, expand patient access to transformative treatments, and ensure that ARM continues to play a vital role in shaping the future of this sector."

The announcement comes as ARM kicks off its 2025 Cell & Gene Meeting on the Mesa, the premier gathering of senior executives, patient advocates and other leaders in the cell and gene therapy sector. Seven new Board Directors will join 25 Directors who will continue their service on the ARM Board in 2026, while eight directors are stepping off the Board.

"Through its leadership, ARM's Board of Directors influences the direction of the organization and helps drive progress across the cell and gene therapy field," said ARM's Chief Executive Officer Tim Hunt. "Our new Board members embody the diversity of ARM's multistakeholder community, including biotechnology leaders, patient advocates, and strategic partners – all committed to advancing transformative therapies for serious diseases."

In addition to overseeing ARM's work to convene the sector, enable the development of cell and gene therapies, and to enhance patient access, ARM's Board provides strategic guidance on topics including ARM's geographic expansion and maintaining the right balance for its multistakeholder membership.


ARM 2026 Board of Directors

*New to the Board for 2026

Faraz Ali, MBA – Chief Executive Officer, Tenaya Therapeutics

Robert Ang, MBBS, MBA – Strategic Advisor, Vor Biopharma

*Allyson Berent, DVM – Chief Scientific Officer, Foundation for Angelman Syndrome Therapeutics; Chief Development Officer, Mahzi Therapeutics



*Warner Biddle – Chief Executive Officer, Kyverna Therapeutics

Catherine Bollard, M.B.Ch.B, M.D. – Director of the Center for Cancer and Immunology Research, Children’s National Hospital and The George Washington University

Moya Daniels, MS – Head of Quality Assurance and Regulatory Affairs, Optieum Biotechnologies

Lisa Deschamps, MBA, BBA – Chief Executive Officer, AviadoBio

Matthew Durdy, MA, MBA – Chief Executive, Cell & Gene Therapy Catapult

George Eastwood – Executive Director, Emily Whitehead Foundation

Anne-Virginie “AV” Eggimann, MS – Chief Regulatory Officer, Tessera Therapeutics

*Seth Ettenberg, Ph.D. – President and Chief Executive Officer, BlueRock Therapeutics

Miguel Forte, M.D., Ph.D. – Chief Executive Officer and Co-Founder, Kiji Therapeutics

*Jason C. Foster, MBA – Chief Executive Officer, Ori Biotech

Audrey Greenberg, CPA, MBA – Venture Partner, Mayo Clinic

*Lynelle Hoch – President, Cell Therapy Organization, Bristol Myers Squibb

Matt Kapusta, MBA – Chief Executive Officer, uniQure

Sadik Kassim, Ph.D. – Chief Technology & Scientific Officer, Danaher Genomic Medicines

Ann Lee, Ph.D. – Chief Technical Officer, Prime Medicine

Anshul Mangal, J.D. – President and Chief Executive Officer, Project Farma

*Rachel McMinn, Ph.D. – Founder and Chief Executive Officer, Neurogene

Adora Ndu, PharmD, J.D. – Chief Regulatory Officer and Executive Vice President, Portfolio Strategy and Management, BridgeBio

Kinnari Patel, PharmD, MBA – Former President, Chief Operating Officer, and Head of R&D, Rocket Pharma

Alberto Santagostino – President and Chief Executive Officer, AGC Biologics

Christy Siegel, PharmD – Senior Vice President & US Therapeutic Area Head, Immunology, Novartis

Manny Simons, Ph.D., MBA – Chief Executive Officer & Co-Founder, Akouos; Senior Vice President, Gene Therapy, Eli Lilly & Co.

Bob Smith, MBA – Venture Partner, Orbimed

Devyn Smith, Ph.D. – Chief Executive Officer, Arbor Biotechnologies

*Joanne Smith-Farrell, Ph.D. – Chief Executive Officer, Be Biopharma

Fyodor Urnov, Ph.D. – Director, Technology & Translation, Innovative Genomics Institute

Christopher Vann – Chief Operating Officer, Autolus Therapeutics

Richard Wilson, MBA – Senior Vice President, Primary Focus Lead, Genetic Regulation, Astellas Pharma

Ran Zheng – Chief Executive Officer, Landmark Bio